Analyst Ratings for Recursion Pharmaceuticals (RXRX)
RXRX Rating Summary
RXRX Price Target Summary
- Highest: $10.00 (JPMorgan)
- Lowest: $5.50 (Morgan Stanley)
- Average: $7.17
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$7.17 (+121.9%)
* Over Last 12-Mos
Rating Score: 4 / 10
Percentile Rank: 39%
Avg. $ Target:
$7.17 (+121.9%)
* Over Last 12-Mos
Rating Score: 4 / 10
Percentile Rank: 39%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 12/17/2025 | JPMorgan » Updated 4/30/2026 |
Priyanka Grover | Upgrade | Overweight (Neutral) |
10.00 (11.00) |
4.20 (3.23) |
-23.1% | Details |
| 7/3/2025 | Morgan Stanley » Updated 5/14/2026 |
Sean Laaman | New Coverage | Equalweight (N/A) |
5.50 (5.00) |
5.13 (3.23) |
-37.04% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
